Ayurveda drug trials against cancer to begin in Chennai | Health - Hindustan Times
close_game
close_game

Ayurveda drug trials against cancer to begin in Chennai

Hindustan Times, New Delhi | By
Jul 14, 2018 11:25 PM IST

DNA has secured the licence from US-based researcher and director of the University of Missouri Cancer Nanotechnology Platform, Dr Kattesh V Katti , to develop and market the drug.

Clinical human trials on an Ayurvedic cancer drug that reduces cancer tumours when used with routine chemotherapy will begin in Chennai next month.

Clinical human trials on an Ayurvedic cancer drug that reduces cancer tumours when used with routine chemotherapy will begin in Chennai.(Shutterstock/Representative photo)
Clinical human trials on an Ayurvedic cancer drug that reduces cancer tumours when used with routine chemotherapy will begin in Chennai.(Shutterstock/Representative photo)

“We have tested the drug on 10 patients with encouraging results, and the second trial with 30 persons is expected to get over in March 2019, after which we will apply for drug approval from the Ayush ministry. We are hoping to market the drug by next year,” said Deepak Abhaya, managing director, Chennai-based Dhanvantri Nano Ayushadi (DNA), which is conducting the trials.

Now catch your favourite game on Crickit. Anytime Anywhere. Find out how

DNA has secured the licence from US-based researcher and director of the University of Missouri Cancer Nanotechnology Platform, Dr Kattesh V Katti , to develop and market the drug. The treatment course typically lasts six months, with patients taking two capsules a day.

One course is expected to cost 75,000-80,000 .

“Green nanotechnology is chemical free and can treat cancer tumours with no side effects of conventional chemotherapy,” said Dr Katti.

“When the medicines were used in cancer patients as combined therapy along with regular chemo, tumour burden reduced by 6-8%, which is a big deal. It has no side effects like nausea or vomiting associated with chemotherapy,” he said.

Oncologists however, are sceptical.

“It needs to be established that the medicine doesn’t interfere with normal treatment modalities, be it chemo, radiation, immune or hormone therapy...” said Dr PK Julka, former head, radiation therapy department, AIIMS, Delhi.

The drug’s entry into the market depends on government approval.

“New drugs go to CDSCO (Central Drugs Standard Control Organization’s) Ayush vertical for review. Only after they are fully satisfied with the data, will they issue an approval,” said Vaidya Rajesh Kotecha, secretary, ministry of Ayush .

Get World Cup ready with Crick-it! From live scores to match stats, catch all the action here. Explore now!.

Catch your daily dose of Fashion, Taylor Swift, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.
SHARE THIS ARTICLE ON
Share this article
SHARE
Story Saved
Live Score
OPEN APP
Saved Articles
Following
My Reads
Sign out
New Delhi 0C
Monday, June 17, 2024
Start 14 Days Free Trial Subscribe Now
Follow Us On